After three consecutive quarters of sales acceleration, Faes lost pace in Q4 19 – due to the fall in high-margin licensing revenue of Bilastine. However, the strong performance in the International and Domestic segments during the quarter combined with the sturdy show of Bilastine in 9M ensured that the full-year financial targets were over-achieved.
